World leading biotech company CSL has strengthened its presence in Melbourne. It will set up its global headquarters, including state-of-the-art laboratories, at the nation’s premier biomedical precinct at Parkville.

The investment cements Melbourne’s position as a world-class research destination, and further boosts the Parkville precinct’s world-leading concentration of research facilities, hospitals and universities.

The new purpose-built facility will foster and support collaborations between academic biomedical research and industry, and help the company to commercialise new products.

On completion in 2024, the HQ will accommodate more than 800 CSL employees including early stage research and product development teams, commercial operations, corporate functions and support service.

CSL’s CEO and Managing Director, Paul Perreault said that Melbourne’s world leading reputation in medical research played a critical part in the company’s decision.

“We have opportunities all around the world and R&D in several countries but we believe the density and quality of medical research activity in Parkville has enormous future potential.

“Melbourne’s reputation as a world class centre of biomedical research excellence is well established,” Mr Perreault said.

The landmark site will be developed by PDG Corporation and will employ nearly 1,350 people in the construction of phases one and two.

Vince Giuliano, Managing Director of PDG said, “This dynamic precinct will be a foundation for organisations that stand as global exemplars of their industries – driving the growth of knowledge, development of technology and success of Australia’s brightest minds.”

The Victorian Government, through Invest Victoria, is supporting this project by working closely with developer PDG and various regulatory authorities to progress development design and approvals.

Renowned as a global leader in biotechnology, CSL operates in more than 35 countries and has more than 22,000 employees, including 2,500 in Victoria.

Victoria’s medical technologies and pharmaceuticals industry employs more than 23,000 people and generates more than $12.7 billion in revenue per year.